Jyong Biotech (NASDAQ:MENS) Releases Earnings Results

Jyong Biotech (NASDAQ:MENS) posted its quarterly earnings data on Friday. The company reported ($0.02) earnings per share for the quarter, FiscalAI reports.

Jyong Biotech Stock Down 3.4%

MENS traded down $0.07 during midday trading on Friday, hitting $2.01. 55,197 shares of the company were exchanged, compared to its average volume of 68,867. Jyong Biotech has a 1-year low of $1.43 and a 1-year high of $67.00. The firm’s 50 day moving average price is $2.21 and its 200-day moving average price is $10.63.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jyong Biotech in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Jyong Biotech has an average rating of “Sell”.

Institutional Trading of Jyong Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Jyong Biotech during the 4th quarter valued at approximately $49,000. Man Group plc acquired a new position in Jyong Biotech in the fourth quarter valued at $56,000. BNP Paribas Financial Markets acquired a new position in Jyong Biotech in the third quarter valued at $67,000. Millennium Management LLC lifted its holdings in Jyong Biotech by 209.4% in the fourth quarter. Millennium Management LLC now owns 40,258 shares of the company’s stock valued at $159,000 after buying an additional 27,245 shares during the period. Finally, Geode Capital Management LLC grew its stake in Jyong Biotech by 19.6% during the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares during the period.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.